On 22 May 2026, Tennor Therapeutics (Suzhou) Ltd. (Tennor Therap, 6872.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 626 million. CBI is honored to participate in the due diligence work for this IPO Project.

Tennor Therapeutics (Suzhou) Ltd is a China-based company primarily engaged in the discovery and development of innovative drug products. The Company focuses on the fields of bacterial infections and bacterial metabolism diseases.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, customers and suppliers, etc. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reference check and related company search. The due diligence project globally covered 6 countries and regions, including China, Hong Kong, Germany, United States of America and Luxembourg.